Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Horizon Therapeutics Public Limited Company shares valued at $400,483 were sold by Pasternak Andy on Jul 29. At $82.57 per share, Pasternak Andy sold 4,850 shares. The insider’s holdings dropped to 34,047 shares worth approximately $2.28 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Also, Thompson Elizabeth H.Z. sold 5,917 shares, netting a total of over 502,945 in proceeds. Following the sale of shares at $85.00 each, the insider now holds 6,969 shares.
Before that, Thompson Elizabeth H.Z. had sold 90 shares from its account. In a trade valued at $7,653, the EVP, Research & Development traded Horizon Therapeutics Public Limited Company shares for $85.04 each. Upon closing the transaction, the insider’s holdings decreased to 90 shares, worth approximately $0.86 million.
As published in a research note from SVB Leerink on August 04, 2022, Horizon Therapeutics Public Limited Company [HZNP] has been rated down from an Outperform to a Mkt perform. Analysts at UBS started covering the stock with ‘”a Buy”‘ outlook in a report released in mid June. Earlier on May 23, 2022, SVB Leerink initiated its rating. Their recommendation was “a Mkt perform” for HZNP stock.
Analyzing HZNP’s Price Performance
On Thursday, Horizon Therapeutics Public Limited Company [NASDAQ: HZNP] rose 0.06% to $67.00. The stock’s lowest price that day was $66.14, but it reached a high of $69.65 in the same session. During the last five days, there has been a drop of approximately -19.96%. Over the course of the year, Horizon Therapeutics Public Limited Company shares have dropped approximately -37.82%. Shares of the company reached a 52-week high of $117.49 on 04/21/22 and a 52-week low of $60.76 on 08/03/22. A 50-day SMA is recorded $83.71, while a 200-day SMA reached $97.44. Nevertheless, trading volume fell to 7.72 million shares from 2.5 million shares the previous day.
Support And Resistance Levels for Horizon Therapeutics Public Limited Company (HZNP)
According to the 24-hour chart, there is a support level at 65.54, which, if violated, would cause prices to drop to 64.09. In the upper region, resistance lies at 69.05. The next price resistance is at 71.11. RSI (Relative Strength Index) is 24.64 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -8.50, which suggests the price will decrease in the coming days. Percent R is at 76.28%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
Is Horizon Therapeutics Public Limited Company subject to short interest?
Stocks of Horizon Therapeutics Public Limited Company saw a sharp rise in short interest on Jul 14, 2022 jumping by 0.44 million shares to 7.42 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 6.98 million shares. A jump of 5.93% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.62 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.62.
Which companies own the most shares of Horizon Therapeutics Public Limited Company (HZNP)?
According to The Vanguard Group, Inc. filings, the company currently owns 19,892,801 shares, which is about 8.68% of the total HZNP shares outstanding. The investor’s shares have appreciated by 212,145 from its previous 13-F filing of 19680656.0 shares. With the completion of the sale transaction, Fidelity Management & Research Co’s stake is now worth $1,165,880,315. BlackRock Fund Advisors acquire a 1.13% interest valued at $726.96 million while Capital Research & Management Co 7,075,657 stake. In its current portfolio, Paulson & Co., Inc. holds 5,614,000 shares valued at $447.77 million.
In terms of Horizon Therapeutics Public Limited Company share price expectations, FactSet research, analysts set an average price target of $111.43 in the next 12 months, up nearly 62.78% from the previous closing price of $66.96. Analysts anticipate Horizon Therapeutics Public Limited Company stock to reach $144.00 by 2022, with the lowest price target being $71.00. In spite of this, 14 analysts ranked Horizon Therapeutics Public Limited Company stock as a Buy at the end of 2022. On March 15, 2022, Oppenheimer assigned a price target of “an Outperform” to the stock and initiated coverage with a $140.